THE BOTTOM LINE
- Urgency is Key: Courts will reject claims for an urgent injunction against a competitor’s advertising if the evidence is dated. Acting swiftly on alleged misconduct is critical to proving the need for immediate court intervention.
- Precision Beats Power: Overly broad legal demands, such as banning all “similar” future statements or forcing a public apology, are likely to be dismissed in summary proceedings. Legal action must be targeted at specific, provable claims.
- Scientific Debates Belong in Full Trials: A court in a summary proceeding will hesitate to rule on complex scientific or technical advertising claims, especially when both sides present credible, conflicting evidence from regulatory bodies or scientific studies.
THE DETAILS
In a head-to-head clash between two major players in the cancer diagnostics market, the District Court of Amsterdam has refused to grant an injunction for alleged misleading advertising. The dispute involved Exact Sciences, the provider of the “Oncotype DX” biomarker test, and its competitor, Agendia, which markets the “MammaPrint” test. Both products are used to help breast cancer patients and their doctors decide on treatment paths, such as chemotherapy. Exact Sciences initiated legal action, claiming that Agendia was unlawfully presenting its test as “predictive” (i.e., able to predict the benefit of a specific therapy), a quality Exact Sciences claims is insufficiently proven for MammaPrint and a key feature of its own product.
The court’s decision to deny the injunction was not based on whether the advertising was ultimately true or false, but on several crucial procedural grounds. Firstly, the judge questioned the claimant’s “urgent interest,” a mandatory requirement for a preliminary injunction in the Netherlands. Most of the advertising materials Exact Sciences complained about were from a year or more prior to the lawsuit. This delay undermined the argument that immediate judicial action was necessary. The court viewed the matter primarily as a commercial dispute, suggesting that if the claims were truly an urgent public health risk, the claimant would have acted much sooner.
Secondly, the case was deemed too complex for a summary judgment. This was not a straightforward case of deceptive advertising but a nuanced scientific debate. Agendia defended its claims by pointing to certifications from a European notified body under the In Vitro Diagnostic Regulation (IVDR) and positive assessments from the Dutch National Health Care Institute. Faced with conflicting expert opinions and scientific data from both parties, the court concluded that resolving such a technical matter would require a full trial on the merits, complete with expert witnesses. This serves as a strong reminder that courts are reluctant to act as scientific arbiters in fast-tracked proceedings.
SOURCE
Source: District Court of Amsterdam
